BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32337496)

  • 1. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
    Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Mina LA; Diab S; Woodward NE; Yerushalmi R; Goodwin A; Blum JL; Martin M; Quek RGW; Tudor IC; Bhattacharyya H; Gauthier E; Litton JK; Eiermann W
    JNCI Cancer Spectr; 2020 Feb; 4(1):pkz085. PubMed ID: 32337496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
    Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    Hurvitz SA; Gonçalves A; Rugo HS; Lee KH; Fehrenbacher L; Mina LA; Diab S; Blum JL; Chakrabarti J; Elmeliegy M; DeAnnuntis L; Gauthier E; Czibere A; Tudor IC; Quek RGW; Litton JK; Ettl J
    Oncologist; 2020 Mar; 25(3):e439-e450. PubMed ID: 32162822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
    Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline
    Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V
    Ther Adv Med Oncol; 2021; 13():17588359211059601. PubMed ID: 34917174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
    Savill KMZ; Ivanova J; Asgarisabet P; Falkenstein A; Balanean A; Niyazov A; Ryan JC; Kish J; Gajra A; Mahtani RL
    Oncologist; 2023 May; 28(5):414-424. PubMed ID: 36952230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
    Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
    McCrea C; Hettle R; Gulati P; Taneja A; Rajora P
    J Comp Eff Res; 2021 Sep; 10(13):1021-1030. PubMed ID: 34231369
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timely Genetic Testing and Therapy Management in Patients With g
    Martinez A; Jones T; Ryan JC; Barnett CM; Soussou EL; Donahue S
    J Adv Pract Oncol; 2022 Sep; 13(7):705-712. PubMed ID: 36199494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    Yu Y; Elmeliegy M; Litton JK; Tudor IC; Czibere A; Zheng J; Wang DD
    J Clin Pharmacol; 2020 Oct; 60(10):1324-1333. PubMed ID: 32468579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline
    Obeid E; Parikh RC; Esterberg E; Arondekar B; Hitchens A; Arruda LS; Niyazov A; Whitaker K
    Front Oncol; 2024; 14():1341665. PubMed ID: 38817906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    Elmeliegy M; Yu Y; Litton JK; Czibere A; Wilson GG; Tudor IC; Zheng J; Wang DD
    J Clin Pharmacol; 2020 Oct; 60(10):1334-1343. PubMed ID: 32468645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study.
    Wang N; Yu X
    Front Immunol; 2022; 13():901636. PubMed ID: 36045677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain.
    Olry de Labry Lima A; Špacírová Z; Fénix-Caballero S; Hoces AM; Vegas AS; Aranzana MC; Sierra-Sánchez JF; Díaz MDCM; Alegre Del Rey EJ
    Breast; 2021 Aug; 58():27-33. PubMed ID: 33895483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.